Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.

ABSTRACT: Ruxolitinib is an FDA approved janus kinase (JAK)1/2 inhibitor used to treat myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera. We aimed to determine the metabolic consequences of ruxolitinib treatment in patients with MPNs. We performed a retrospective single-center cohort study utilizing an electronic medical record based database of patients who began treatment with ruxolitinib for MPNs from January 2010 to March 2017. We also examined the effects of ruxolitinib on adipose tissue JAK/STAT signaling in a mouse model. 127 patients were identified, of which 69 had data available for weight, and at least one other parameter of interest before, and 72 weeks after starting ruxolitinib. Mean baseline weight was 73.9?±?17.0?kg, and 78.54?±?19.1?kg at 72 weeks (p?5% body weight. Baseline body mass index (BMI) was 25.8?±?4.8?kg/m², and 27.5?±?5.5?kg/m² at 72 weeks (p?

SUBMITTER: Sapre M 

PROVIDER: S-EPMC6851362 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature